Clinical trials: Cholangiocarcinoma Cancer
Intrahepatic Cholangiocarcinoma
Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma
This study is a single-arm, open-arm, single-center clinical study to explore the efficacy and safety of HAIC in combination with Surufatinib and Toripalimab in patients with inoperable or metastatic intrahepatic…
- Trial name
- NCT06313554
- Testing
- Surufatinib、Toripalimab、Gemcitabine、Oxaliplatin
- Volunteers
- 63 people
- Sponsor
- Fudan University
Biliary Tract Cancer, Cholangiocarcinoma
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
This is a Phase 2 study to evaluate the efficacy, using objective response rate, of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous Tumor Infiltrating Lymphocytes (TIL) and high-dose…
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Biliary Tract Neoplasms
- Trial name
- NCT03801083
- Testing
- Tumor Infiltrating Lymphocytes (TIL)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Udai Kammula
Gallbladder Cancer, Cholangiocarcinoma
Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)
The goal of this clinical trial is to evaluate the efficacy and safety of combining Gemcitabine, nab-Paclitaxel, Lenvatinib, and Tislelizumab in adults aged 18-75 years with advanced unresectable biliary tract malignancies…
- Trial name
- GALENT-BT (NCT06963060)
- Testing
- Gemcitabine nab-PaclitaxelLenvatinibTislelizumab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Wei Gong
Cholangiocarcinoma, Cholangiocarcinoma Non-resectable
A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma
ABC-108 is a single-arm Phase IIA clinical study of ABC294640 (Yeliva ®, opaganib) alone and in combination with hydroxychloroquine sulfate (HCQ) in the treatment of cholangiocarcinoma (CCA).
- Conditions
- Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic
- Trial name
- NCT03377179
- Testing
- ABC294640, Hydroxychloroquine Sulfate 200 MG
- Where
- 5 sites in United States
- Volunteers
- 65 people
- Sponsor
- RedHill Biopharma Limited
Gastrointestinal Cancers, Cholangiocarcinoma
Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
Prospective, multi-center, open label, non-randomized clinical trial to assess efficacy of [18F]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal cancers, including hepatocellular carcinoma…
- Conditions
- Gastrointestinal Cancers, Cholangiocarcinoma, Gastric Cancer, Colorectal Cancer
- Trial name
- 18F-FAPI-74 GI (NCT05641896)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 6 sites in United States
- Volunteers
- 112 people
- Sponsor
- SOFIE
Intrahepatic Cholangiocarcinoma (Icc)
PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma
The goal of this trial is to determine whether the combination of CISGEM and Rilvegostomig during the perioperative period works to improve outcomes of patient undergoing surgery of high-risk of intrahepatic cholangiocarcinoma
- Trial name
- PEHRICCA (NCT07128290)
- Testing
- CISGEM + Rilvegostomig
- Where
- 9 sites in France
- Volunteers
- 49 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Cholangiocarcinoma
Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement
This is a phase 2 study to investigate the efficacy and safety of Pemigatinib in treating patients with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 rearrangement who have failed at least 1…
- Trial name
- NCT04256980
- Testing
- Pemigatinib
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Cholangiocarcinoma, Cholangiocarcinoma Non-resectable
Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
This is an expanded access program (EAP) for eligible participants who do not qualify for participation in, or who are otherwise unable to access, the ongoing clinical trial ABC-108.
- Conditions
- Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic
- Trial name
- NCT03414489
- Testing
- ABC294640
- Sponsor
- RedHill Biopharma Limited
Choledocholithiasis, Cholangiocarcinoma
Etomidate vs. Midazolam for Sedation During ERCP
Recently up-coming drug, etomidate which is a modulator of GABA(gamma-Aminobutyric acid)-A receptor has been known that it maintains the appropriate sedative levels and affects little effects on respiratory system.
- Conditions
- Choledocholithiasis, Cholangiocarcinoma, Pancreatitis, Pancreatic Cancer
- Trial name
- NCT02027311
- Testing
- Etomidate, Midazolam, Meperidine
- Where
- South Korea
- Volunteers
- 63 people
- Sponsor
- Cheju Halla General Hospital
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Non-small Cell Lung Cancer, Breast Cancer
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.
- Conditions
- Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma
- Trial name
- NCT04440943
- Testing
- CDX-527
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- Celldex Therapeutics
Ovarian Neoplasms, Breast Neoplasms
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP).
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
- Trial name
- FiREBOLT (NCT07213791)
- Testing
- LY4337713
- Where
- 30 sites in United States, China and 3 more
- Volunteers
- 340 people
- Sponsor
- Eli Lilly and Company
Bile Duct Neoplasms, Colorectal Neoplasms
Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma
Due to discontinuation of the Codman C3000 pump, an alternate device is necessary to continue serving patients in need of hepatic arterial infusion chemotherapy.
- Trial name
- NCT04276090
- Testing
- Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter., Hepatic artery infusion pump floxuridine and dexamethasone, Systemic chemotherapy for colorectal liver metastases
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Michael J Cavnar, MD
Pancreatic Cancer, Pancreatic Adenocarcinoma
GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial Pancreatectomy
This is a single-site, randomized, controlled treatment trial evaluating perioperative steroid hydrocortisone use in patients undergoing pancreatic resection (partial pancreatectomy).
- Conditions
- Pancreatic Cancer, Pancreatic Adenocarcinoma, Duodenal Cancer, Distal Cholangiocarcinoma
- Trial name
- NCT07796997
- Testing
- Hydrocortisone, Pancreatic resection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Illinois Chicago
Cholangiocarcinoma
Prognostic Factors for Survival in Patients With Cholangiocarcinoma
The objective of this retrospective study is to determine the survival rates of CCA patients based on different therapeutic approaches.
- Trial name
- NCT06369480
- Testing
- Resection/Ablation of tumor, Palliative chemotherapy, Neoadjuvant chemotherapy
- Where
- Denmark
- Volunteers
- 2,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Common Bile Duct Stricture, Jaundice; Malignant
Efficacy and Safety of Plastic, Covered and Uncovered Self-expandable Metal Stents in the Treatment of Malignant Biliary Obstructions (NEOSTENT)
The aim of the study is to evaluate the efficacy and safety of the various types of stents available for biliary drainage in patients with neoplastic stenosis of the common bile duct and to evaluate the adherence to the current…
- Trial name
- NEOSTENT (NCT05395013)
- Where
- Italy
- Volunteers
- 3,149 people
- Sponsor
- Azienda Unità Sanitaria Locale della Romagna
Cholangiocarcinoma
PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer
This study will assess the safety and effectiveness of fimaporfin-induced photochemical internalisation (PCI) of gemcitabine complemented by systemic gemcitabine/cisplatin chemotherapy compared to gemcitabine/cisplatin alone, in…
- Trial name
- RELEASE (NCT04099888)
- Testing
- Fimaporfin and Gemcitabine, Gemcitabine/Cisplatin chemotherapy
- Where
- 50 sites in United States, Belgium and 12 more
- Volunteers
- 41 people
- Sponsor
- PCI Biotech AS
Hilar Cholangiocarcinoma
MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma
This is a prospective, observational diagnostic study aiming to assess multiparametric MRI-based clinico-radiomics for identifying lymph node metastasis status in hilar cholangiocarcinoma.
- Trial name
- NCT05626127
- Testing
- No interventions
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Biliary Carcinoma
Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract Adenocarcinoma
This is a multi-centre phase II, open-label, randomized (1:1), parallel-arm, study of panitumumab in combination with chemotherapy (P-GEMOX) versus chemotherapy alone (GEMOX).
- Trial name
- Vecti-BIL (NCT01389414)
- Testing
- Panitumumab plus GEMOX chemotherapy, GEMOX chemotherapy
- Where
- 12 sites in Italy
- Volunteers
- 89 people
- Sponsor
- Prof. Massimo Aglietta
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.